NCT04834674 2026-04-07
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
Clinical Trials
27 trialsNCT03092895 2026-01-29
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed
NCT05223088 2025-03-18
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVăLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Completed
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT06376773 2024-04-19
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Fujian Medical University
Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT02976896 2023-02-16
Poetry-1
Sun Yat-sen University
Phase 2 Completed
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT02711969 2022-07-22
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
Bukwang Pharmaceutical
Phase 1 Completed
NCT03042611 2022-07-08
ANGEL
Elevar Therapeutics
Phase 3 Completed
NCT03104283 2022-03-15
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Completed
NCT02764268 2022-03-11
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase NA Completed
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT02645864 2021-03-18
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Peking University
Phase 1 Completed
NCT03274011 2021-01-26
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Completed
NCT03251443 2020-12-02
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT04338438 2020-11-10
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Phase 2 Completed
NCT03190616 2020-01-14
Apatinib in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT01512745 2016-10-17
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01531777 2015-04-03
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT00970138 2011-07-12
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2/3 Completed